Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.

A structured, three-stage validation protocol can test raffinose in just eight weeks. It progresses from a 96-well plate screen to spin tubes to benchtop bioreactors. Each stage has a clear go/no-go criterion, allowing teams to quickly determine viability for their process without over-investing resources.

Scaling from a T-flask to a bioreactor isn't just increasing volume; it's a fundamental shift in the biological context. Changes in cell density, mass transfer, and mechanical stress rewire cell signaling. Therefore, understanding and respecting the cell's biology must be the primary design input for successful scale-up.

The belief that bioprocess development must take a long time becomes a self-fulfilling prophecy. Professor Waranyoo Phoolcharoen argues that integrating manufacturing, scalability, and downstream constraints from day one can significantly shorten timelines, challenging the industry's traditional, sluggish mindset.

The standard practice is to optimize for productivity (titer) first, then correct for quality (glycosylation) later. This is reactive and inefficient. Successful teams integrate glycan analysis into their very first screening experiments, making informed, real-time trade-offs between productivity and quality attributes.

Instead of immediately scaling up the manufacturing process between clinical Phase 1 and 2, it is strategically better to produce more batches using the established Phase 1 process. This approach builds critical knowledge about process parameters and CQAs through repetition and increased clinical exposure.

To ensure a smooth transition from development to production, an operations or manufacturing SME must be part of the design process from the start. Otherwise, products are developed without manufacturability in mind, leading to expensive, reactive fixes and subjective quality control during scale-up.

A 'healthy tension' exists between research teams, who want to continually iterate on a therapy's design, and manufacturing teams, who need a finalized process to scale production for trials. Knowing precisely when to 'lock down' the design is a critical, yet difficult, decision point for successful commercialization.